Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Johnson & johnson save search
Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: -0.4%
H: 3.01%
C: 2.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.39%
H: 1.69%
C: 1.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.83%
C: 0.89%
first treatment for
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment global growth market
Robbins Geller Rudman & Dowd LLP, Lieff Cabraser Heimann & Bernstein LLP, and Dugan Law Firm, APLC Announce a $78 Million Class Action Settlement for Third Party Payors That Paid or Reimbursed Costs for Prescription Opioids or Treatment Related to Opioid Misuse, Addiction, and/or Overdose
Published: 2024-04-15 (Crawled : 20:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
opioid million treatment for
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment
Published: 2024-04-06 (Crawled : 16:20) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
fda treatment for car-t
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Published: 2024-04-06 (Crawled : 04:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda first approved one treatment for therapy
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
NBTX | $5.69 3.45% 3.34% 1.6K
|
Manufacturing
|
| O: 3.11%
H: 1.19%
C: -2.54%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
lung cancer treatment
Global Infectious Enteritis Treatment Market Report 2024: A USD$937.7 Million Market by 2034 - Antibiotics Segment Dominates the Market
Published: 2024-03-29 (Crawled : 23:00) - prnewswire.com
ARDX | $6.5 0.93% 0.92% 5.6M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
report million treatment antibiotics global market
Regeneron Hit With Two CRLs, J&J’s PAH Treatment Approved
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.35%
H: 0.35%
C: -1.34%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
approved treatment
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial Fibrillation
Published: 2024-03-25 (Crawled : 12:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
fda approval treatment application platform
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: -0.27%
H: 4.91%
C: -2.9%
carvykti fda treatment
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-03-15 (Crawled : 19:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda treatment
FDA Decisions: J&J’s Rybrevant Becomes First Front-Line Treatment for Type of NSCLC
Published: 2024-03-04 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.65%
H: 1.13%
C: -1.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
fda first treatment rybrevant
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
rybrevant fda first lung approved cancer cell treatment therapy
Urinary Tract Infection Treatment Market Projected to Reach US$ 10.73 Billion by 2030: Telemedicine Integration Revolutionizes UTI Care, Self-Care Products Gain Momentum
Published: 2024-02-29 (Crawled : 20:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.33%
H: 3.68%
C: 2.44%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.03%
H: 0.14%
C: 0.05%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.26%
H: 0.18%
C: 0.05%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.37%
H: 0.27%
C: -0.1%
integration reach momentum infection treatment market
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-02-20 (Crawled : 23:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
tecvayli fda approved treatment
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More t...
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.67%
H: 2.06%
C: 1.86%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
fda first approved cancer pancreatic treatment
FDA Decisions: First Frontline Pancreatic Cancer Treatment Approved in More than a Decade
Published: 2024-02-15 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.67%
H: 2.06%
C: 1.86%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
fda first approved cancer pancreatic treatment
Lice Treatment Global Market Report 2024: Global Lice Treatment Market Witnesses Substantial Growth as Consumer Preferences Shift Toward Natural Solutions
Published: 2024-02-14 (Crawled : 02:00) - prnewswire.com
RBGPF | $51.61 6.46% 4.7K
|
Consumer Non-Durables
|
| O: -0.94%
H: 0.01%
C: 0.01%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
RBGLY | $10.35 -2.05% 990K
|
Manufacturing
|
| O: -0.69%
H: 0.35%
C: 0.35%
PBH | $69.67 1.93% 0.0% 450K
|
Health Technology
|
| O: 0.06%
H: 2.84%
C: 1.65%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.41%
H: 0.44%
C: -1.03%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: 0.0%
ELAN | $12.95 -4.57% 0.0% 5.7M
|
Process Industries
|
| O: 1.53%
H: 1.16%
C: 0.82%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
report natural treatment global solutions growth market
FDA Decisions: Agency Greenlights Takeda's Oral EoE Treatment in Company's Se...
Published: 2024-02-12 (Crawled : 17:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.31%
H: 1.44%
C: 1.31%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
fda treatment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.